A Phase I Study to Determine the Safety and Immunogenicity of the Candidate Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Vaccine ChAdOx1 MERS in UK Healthy Adult Volunteers
Phase of Trial: Phase I
Latest Information Update: 23 Oct 2019
Price : $35 *
At a glance
- Drugs Middle East respiratory syndrome coronavirus vaccine - Vaccitech (Primary)
- Indications Middle East respiratory syndrome coronavirus
- Focus Adverse reactions
- 18 Oct 2019 Planned number of patients changed from 24 to 48.
- 18 Oct 2019 Planned End Date changed from 1 Dec 2019 to 1 Jul 2021.
- 18 Oct 2019 Planned primary completion date changed from 1 Dec 2019 to 1 Jul 2021.